Log in

MBRX Moleculin Biotech, Inc. NASDAQ · United States

Moleculin Biotech (MBRX) news MBRX reverse split, delisting and going concern news

Latest Moleculin Biotech news

  1. Financings

    Moleculin sells 888,400 shares through at-the-market program in September

    The sales raised $0.48 million, and anti-dilution terms cut the exercise price of the August 2026 Series I Warrants to $0.51.

  2. Listings

    Moleculin Biotech gets Nasdaq staff determination on bid price, plans hearing request

    Nasdaq staff says Moleculin is not eligible for a compliance period because it effected a 1-for-25 reverse stock split on December 1, 2025. The company plans to request a hearing, which stays any delisting action while it is pending.

  3. Financings

    Moleculin lifts ATM to $19.7M weeks after a $9.3M deal with 3x warrants

    Moleculin can now sell up to $19,700,000 under its at-the-market program, weeks after a July deal with warrants on 37,130,001 shares. The trial figures it cited are blinded and preliminary, drawn from 62 patients.

  4. Company Updates

    Moleculin calls first-45-patient MIRACLE results positive but gives no figures

    The company says both Annamycin arms showed favorable efficacy trends against the control arm in relapsed or refractory AML, on a full intent-to-treat basis.

  5. Listings

    Moleculin Biotech gets Nasdaq delisting determination, plans hearing panel appeal

    Nasdaq staff issued a delisting determination against Moleculin Biotech's common stock for failing the $2.5 million stockholders' equity rule. The company said it will ask a hearing panel to stay any suspension, and its last annual report showed $4.3 million of cash and a going-concern warning.

  6. Financings

    Moleculin Biotech to raise up to $6.0 million through warrant inducement deal

    Holders will exercise warrants for 16,216,216 shares at $0.37. They get new Series F warrants for 64,864,864 shares at $0.55, pending shareholder approval.

  7. Listings

    Moleculin Biotech gets Nasdaq bid price notice, has until December 24, 2025

    The stock closed below $1.00 for 30 straight business days. The company may consider a reverse stock split to regain compliance.

Moleculin Biotech annual financials

LineFY2025FY2024
Revenue$0$0
Research and development$15.9 million$17.7 million
Net income (loss)-$33.6 million-$26.0 million
Cash from operations-$22.7 million-$23.9 million
Cash and equivalents$8.9 million$4.3 million

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $7.3 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about Moleculin Biotech

Did Moleculin Biotech do a reverse stock split?

Our latest story on this, dated Sep 18, 2026: "Moleculin Biotech gets Nasdaq staff determination on bid price, plans hearing request". The story links the filing or release it is based on. Read the story.

Was Moleculin Biotech delisted?

Our latest story on this, dated Sep 18, 2026: "Moleculin Biotech gets Nasdaq staff determination on bid price, plans hearing request". The story links the filing or release it is based on. Read the story.

Has Moleculin Biotech issued a going-concern warning?

Our latest story on this, dated Nov 21, 2025: "Moleculin Biotech gets Nasdaq delisting determination, plans hearing panel appeal". The story links the filing or release it is based on. Read the story.

Has Moleculin Biotech raised money recently?

Our latest story on this, dated Sep 23, 2026: "Moleculin sells 888,400 shares through at-the-market program in September". The story links the filing or release it is based on. Read the story.

What is the ticker symbol of Moleculin Biotech?

Moleculin Biotech, Inc. trades under the ticker MBRX on NASDAQ.

Where is Moleculin Biotech listed?

Moleculin Biotech, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:MOL; LSE:0K2H.

What is the SEC CIK of Moleculin Biotech?

The SEC Central Index Key (CIK) for Moleculin Biotech, Inc. is 1659617. Its filings are on SEC EDGAR.

How many shares does Moleculin Biotech have outstanding?

19,477,380 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-13.

Which country or territory is Moleculin Biotech listed under?

Our directory records Moleculin Biotech, Inc. under United States.

What does Moleculin Biotech do?

Our directory classifies Moleculin Biotech, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Moleculin Biotech?

The ISIN recorded for Moleculin Biotech, Inc. is US60855D5077.

Does aibio.space cover Moleculin Biotech?

aibio.space lists Moleculin Biotech, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Moleculin Biotech incorporated?

SEC records list its state or country of incorporation as DE.

What was Moleculin Biotech's revenue last year?

$0 for the fiscal year ended Dec 31, 2025, as reported to the SEC.

Is Moleculin Biotech profitable?

Moleculin Biotech, Inc. reported a net loss of $33.6 million for the fiscal year ended Dec 31, 2025, and used $22.7 million of cash in operations, per its annual report to the SEC.

Investor discussion: Moleculin Biotech

Members talk about Moleculin Biotech (MBRX). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Moleculin Biotech, newest first. Each line links the filing it comes from.

  1. Listings

    Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). Source

  2. Listings

    Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,9.01). Source

  3. Listings

    Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source

  4. Listings

    Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source

  5. Financings

    Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source

  6. Listings

    Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source

  7. Financings

    Reported a financing. SEC Form S-1. Source

  8. Financings

    Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source

  9. Listings

    Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source

  10. Listings

    Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source

  11. Financings

    Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source

  12. Listings

    Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). Source

  13. Listings

    Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source

  14. Financings

    Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source

  15. Listings

    Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source

  16. Financings

    Reported a financing. SEC Form 424B5. Source

  17. Listings

    Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source

  18. Listings

    Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source

  19. Listings

    Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source

  20. Financings

    Reported a financing. SEC Form 424B4. Source

  21. Financings

    Filed a registration statement for a share offering. SEC Form S-1. Source

  22. Listings

    Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source

  23. Financings

    Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source

  24. Financings

    Filed a registration statement for a share offering. SEC Form S-1. Source

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:MBRX on TradingView.

SEC filings and registration

SEC name
Moleculin Biotech, Inc.
CIK
1659617
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
MBRX (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
Non-accelerated filer<br>Smaller reporting company
Business address
5300 MEMORIAL DRIVE, HOUSTON, TX, 77007
Phone
713-300-5160
Shares outstanding
19,477,380 as of 2026-08-06 (10-Q filed 2026-08-13)

Recent filings (8-K and 6-K are the company's own announcements)

  • 8-K filed 2026-10-20
  • 8-K filed 2026-10-16
  • 8-K filed 2026-10-09
  • 8-K filed 2026-10-05
  • 8-K filed 2026-09-29
  • 8-K filed 2026-09-28
  • 8-K filed 2026-09-25
  • 8-K filed 2026-09-23

Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

Listing details

Moleculin Biotech, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker MBRX, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Moleculin Biotech, Inc.
Ticker
MBRX
Listing
NASDAQ
Country or territory
United States
Business scope
Pharmaceuticals: Major
ISIN
US60855D5077
Other listed symbols
GETTEX:MOL; LSE:0K2H
Last quote in directory
2026-10-21
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.